NDAORALCAPSULE
Approved
Sep 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERRAMYCIN (oxytetracycline hydrochloride) is a tetracycline-class antibiotic that has been in clinical use since 1964. It is a broad-spectrum antibiotic indicated for treatment of various bacterial infections across multiple organ systems. The drug works by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and defending market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TERRAMYCIN offers limited career growth opportunities given the product's mature, LOE-approaching status and minimal linked job openings. Career value lies primarily in defensive brand management, regulatory compliance, and legacy product stewardship rather than innovation or expansion roles.
Brand ManagerField Sales Representative
Worked on TERRAMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.